Islam Rabia, Kundu Sumana, Jha Surajkumar B, Rivera Ana P, Flores Monar Gabriela Vanessa, Islam Hamza, Puttagunta Sri Madhurima, Sange Ibrahim
Research, Faisalabad Medical University, Faisalabad, PAK.
Research, R.G. Kar Medical College, Kolkata, IND.
Cureus. 2022 Apr 3;14(4):e23785. doi: 10.7759/cureus.23785. eCollection 2022 Apr.
Cirrhosis is an end-stage liver disease that can cause changes in any component of the hemostatic system. The net effects of the complicated hemostatic changes have long been unknown due to concurrent changes in pro-and antihemostatic drivers. Coagulation disorders are caused by various factors, including decreased clotting and inhibitor factor synthesis, reduced clearance of activated factors, quantitative and qualitative platelet defects, hyperfibrinolysis, and increased intravascular coagulation. This review discusses the pathogenesis of coagulopathy and multiple studies related to its clinical presentations. This article also highlights an additional problem in the diagnostic and therapeutic approach to this group of patients: the fact that traditional coagulation tests and transfusional strategies may not be reliable for assessing and managing bleeding or thrombotic risks. Hence, multiple management options have been assessed for bleeding and thrombosis in liver disease.
肝硬化是一种终末期肝病,可导致止血系统的任何组成部分发生变化。由于促凝血和抗凝血驱动因素的同时变化,复杂止血变化的净效应长期以来一直不明。凝血障碍由多种因素引起,包括凝血因子和抑制因子合成减少、活化因子清除减少、血小板数量和质量缺陷、纤维蛋白溶解亢进以及血管内凝血增加。本综述讨论了凝血病的发病机制以及与其临床表现相关的多项研究。本文还强调了这组患者诊断和治疗方法中的另一个问题:传统凝血试验和输血策略可能无法可靠地评估和管理出血或血栓形成风险。因此,已经评估了针对肝病出血和血栓形成的多种管理方案。